New CAR-T therapy targets hard-to-treat brain lymphoma in early trial
NCT ID NCT07062627
First seen Dec 26, 2025 · Last updated May 07, 2026 · Updated 22 times
Summary
This study tests a new treatment called Anbal-cabtagene autoleucel (Anbal-cel) for people with a type of brain lymphoma (primary or secondary CNS lymphoma) that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better attack the cancer. The study will enroll 12 adults and follow them for at least 12 months, with long-term monitoring for up to 15 years to check safety and how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA，DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.